14-3-3 eta Antibody (YA5472)
(Synonyms: 14-3-3 protein eta; Protein AS1; )14-3-3 eta Antibody (YA5472) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to 14-3-3 eta.
-
Host:
Mouse
-
Application:
WB, IHC-P
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS containing 50% glycerol, and 0.02% sodium azide.
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
|---|---|---|
| Dilution Ratio | 1:500-2000 | 1:50-200 |
Product Details
14-3-3 eta Antibody (YA5472) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to 14-3-3 eta.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 28 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Synthesized peptide derived from human 14-3-3 eta
affinity chromatography.
Non-conjugated
Unmodified
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS containing 50% glycerol, and 0.02% sodium azide.
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negatively regulates the kinase activity of PDPK1
-
Expression
Tissue_specificity:It is primarily expressed in the brain, but also present in small amounts in other tissues. -
Subunit
Homodimer (By similarity). Interacts with many nuclear hormone receptors and cofactors including AR, ESR1, ESR2, MC2R, NR3C1, NRIP1, PPARBP and THRA. Interacts with ABL1 (phosphorylated form); the interaction retains it in the cytoplasm. Interacts with ARHGEF28 and CDK16 (By similarity). Weakly interacts with CDKN1B. Interacts with GAB2. Interacts with KCNK18 in a phosphorylation-dependent manner. Interacts with SAMSN1 (By similarity). Interacts with the 'Ser-241' phosphorylated form of PDPK1. Interacts with the 'Thr-369' phosphorylated form of DAPK2 (PubMed:26047703). Interacts with PI4KB, TBC1D22A and TBC1D22B (PubMed:23572552). Interacts with SLITRK1 (PubMed:19640509). Interacts with MEFV (PubMed:27030597)
-
SwissProt ID
-
Synonyms
14-3-3 protein eta; Protein AS1;
Documentation
References
[1]. Obsilova V, et al. Structural insights into the functional roles of 14-3-3 proteins. Front Mol Biosci. 2022;9:1016071. [Content Brief]
[2]. Muslin AJ, et al. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889-897. [Content Brief]
[3]. Yang X, et al. Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A. 2006;103(46):17237-17242. [Content Brief]
[4]. Gardino AK, et al. 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol. 2011;22(7):688-695. [Content Brief]
[5]. Pennington KL, et al. The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions. Oncogene. 2018;37(42):5587-5604. [Content Brief]
[6]. Li Z, et al. 14-3-3σ, the double-edged sword of human cancers. Am J Transl Res. 2009;1(4):326-340. [Content Brief]
[7]. Maksymowych WP, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41(11):2104-2113. [Content Brief]
[8]. Aghazadeh Y, et al. The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today. 2016;21(2):278-287. [Content Brief]
Powered by Bioz
